Precision appoints John Hubbard, PhD, as Board of Directors Chair
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
Open, scalable, end-to-end solution to improve diagnostic quality and efficiency
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
Chronic Kidney Disease is a growing epidemic with 850 million people affected worldwide.
This new capability represents a significant shift from a microscope-based standard of care to the use of digital whole slide images
New GMP facility for clinical and small-scale commercial pharmaceutical lipids
The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market
lAIH strives to introduce appropriate interventions for nurturing an AMR innovation ecosystem in the country through cohesive efforts across the innovation pyramid
With this additional route of administration, the MMRV Family now joins other routinely recommended vaccines that can be administered intramuscularly
AstraZeneca and Merck are committed to working with the FDA to bring LYNPARZA in combination with abi/pred to patients diagnosed with mCRPC.
Subscribe To Our Newsletter & Stay Updated